We have discovered a frequent mutation in the estrogen receptor ER? in over 30% of hyperplasias of the breast, and strikingly in 50% of invasive breast cancers. This mutation replaces arginine for lysine at residue 303 (K303R), which greatly enhances sensitivity to very low levels of estrogen. Furthermore, the mutant ER? causes the antiestrogen tamoxifen (Tam) to act as an agonist rather than an antagonist, which would lead to Tam resistance in tumors. (Others have found that signaling from overexpressed HER2 causes wild type (WT) ER? to behave the same way.) Furthermore, upon estrogen withdrawal, our mutant-expressing tumors re- gress but then regrow, suggesting that the mutation also confers resistance to therapies such as aromatase inhibitors (AIs). The mutation enhances phosphorylation of ER? at the adjacent S305 site by the intracellular signaling kinases AKT and PKA, and S305 phosphorylation enhances phosphorylation at S118 and may affect the Y537 site phosphorylated by c-Src, since the mutation also enhances ER? cross-talk with c-Src activity. Collectively, our data suggest that the hinge domain where the mutation and the S305 phosphorylation site reside regulates interactions among ER?'s functional domains as well as with coregulators and target promoters. We therefore hypothesize that the mutation adapts ER? for enhanced reception of intra-cellular signal transduction, which alters ER? activity and confers resistance to hormonal therapies. To test this hypothesis and to explore its implications for breast cancer biology and especially for clinical resistance to endocrine therapies, we propose: (1) To determine the interaction of the K303R mutation and S305 phosphorylation of ER? in hormone resistance. We will generate MCF-7 WT and K303R ER? lines with additional ER??mutations to either eliminate or mimic activation of the phosphorylation sites at S305, S118, and Y537. Responses to Tam and estrogen will be determined in vitro and in xenografts, ? signaling from constitutively activated PKA. For exploring effects on AI therapy, aromatase cDNA will be stably introduced into the various double mutant lines. (2) To determine the gene-selective effects of S305 ER? phosphorylation events. To identify relationships between intracellular kinase signaling, ER? function, and hormone resistance, we will perform expression microarray analyses of our models from Aim 1. Tam agonist activities on selected genes will be confirmed with luciferase reporters, and immunoblot analysis will use phosphorylation-specific ER? antibodies. To discover genes induced by Tam's agonist effects we will employ ChIP-on-chip assays, with the goal of identifying potential targets for intervention in resistance. (3) To determine the impact of the K303R mutant and receptor phosphorylation on clinical hormone resistance. Tumors from women treated with Tam, with long-term clinical follow-up, will be sequenced for the K303R mutation to determine if the mutation affects Tam response, and phosphorylation at S305 will be assessed by IHC. Finally, we will determine if the mutant is associated with the "luminal B" expression profile subset and its poor clinical outcome. PROJECT NARRATIVE We discovered the K303R ER? mutation in breast hyperplasias and determined it was present in invasive cancer and associated with biological features of poor clinical outcome. The mutation confers an estrogen hypersensitive, tamoxifen-resistant phenotype to breast cancer cells. We will test whether the mutation is associated with poor response to tamoxifen and the aromatase inhibitor anastrazole.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA072038-15
Application #
8249491
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Sathyamoorthy, Neeraja
Project Start
1996-09-01
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2014-04-30
Support Year
15
Fiscal Year
2012
Total Cost
$291,192
Indirect Cost
$101,490
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Fuqua, Suzanne A W; Gu, Guowei; Rechoum, Yassine (2014) Estrogen receptor (ER) ? mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat 144:11-9
Rechoum, Yassine; Rovito, Daniela; Iacopetta, Domenico et al. (2014) AR collaborates with ER? in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat 147:473-85
Covington, Kyle R; Brusco, Lauren; Barone, Ines et al. (2013) Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Res Treat :
De Amicis, Francesca; Russo, Alessandra; Avena, Paola et al. (2013) In vitro mechanism for downregulation of ER-? expression by epigallocatechin gallate in ER+/PR+ human breast cancer cells. Mol Nutr Food Res 57:840-53
Barone, Ines; Catalano, Stefania; Gelsomino, Luca et al. (2012) Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells. Cancer Res 72:1416-27
Barone, Ines; Brusco, Lauren; Gu, Guowei et al. (2011) Loss of Rho GDI* and resistance to tamoxifen via effects on estrogen receptor *. J Natl Cancer Inst 103:538-52
Selever, Jennifer; Gu, Guowei; Lewis, Michael T et al. (2011) Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clin Cancer Res 17:6510-21
De Amicis, Francesca; Giordano, Francesca; Vivacqua, Adele et al. (2011) Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J 25:3695-707
Barone, Ines; Brusco, Lauren; Fuqua, Suzanne A W (2010) Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 16:2702-8
Ohshiro, Kazufumi; Mudvari, Prakriti; Meng, Qing-chang et al. (2010) Identification of a novel estrogen receptor-alpha variant and its upstream splicing regulator. Mol Endocrinol 24:914-22

Showing the most recent 10 out of 29 publications